← Back to Search

GLP1 receptor agonist

RGT001-075 for Diabetes

Phase 2
Waitlist Available
Research Sponsored by Regor Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial tests a new daily pill for adults with Type 2 Diabetes who can't control their blood sugar with diet, exercise, and metformin. The pill helps manage blood sugar by increasing insulin and reducing sugar production in the liver. This type of medication is known for its glucose-lowering effects and additional benefits such as weight loss and cardiovascular protection.

Eligible Conditions
  • Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: Dose Group FExperimental Treatment1 Intervention
Group II: Dose Group EExperimental Treatment1 Intervention
Group III: Dose Group DExperimental Treatment1 Intervention
Group IV: Dose Group CExperimental Treatment1 Intervention
Group V: Dose Group BExperimental Treatment1 Intervention
Group VI: Dose Group AExperimental Treatment1 Intervention
Group VII: Placebo GroupPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Regor Pharmaceuticals Inc.Lead Sponsor
4 Previous Clinical Trials
142 Total Patients Enrolled
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top